Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background/Aims</h3><p>Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well‐characterized, but their impact on outcome and prognosis remain unknown.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach/Results</h3><p>This bi‐institutional study of patients with confirmed iCCA (n=412) used targeted next‐generation sequencing of primary tumors to define associations among genetic alterations, clinicopathological variables, and outcome. The most common oncogenic alterations were <i>IDH1</i> (20%), <i>ARID1A</i> (20%), <i>TP53</i> (17%), <i>CDKN2A</i> (15%), <i>BAP1</i> (15%), <i>FGFR2</i> (15%), <i>PBRM1</i> (12%), and <i>KRAS</i> (10%). <i>IDH1/2</i> mutations (<i>mut</i>) were mutually exclusive with <i>FGFR2</i> fusions (<i>fus</i>), but neither was associated with outcome. For all patients, <i>TP53</i> (p<0.0001), <i>KRAS</i> (p=0.0001), and <i>CDKN2A</i> (p<0.0001) alterations predicted worse overall survival (OS). These high‐risk alterations were enriched in advanced disease but adversely impacted survival across all stages, even when controlling for known correlates of outcome (multifocal disease, lymph node involvement, bile duct type, periductal infiltration). In resected patients (n=209), <i>TP53mut</i> (HR=1.82, 95%CI=1.08‐3.06, p=0.03) and <i>CDKN2A</i> deletions (<i>del</i>) (HR=3.40, 95%CI=1.95‐5.94, p<0.001) independently predicted shorter OS, as did high‐risk clinical variables (multifocal liver disease [p<0.001]; regional lymph node metastases [p<0.001]), whereas <i>KRASmut</i> (HR=1.69, 95%CI=0.97‐2.93, p=0.06) trended toward statistical significance. The presence of both or neither high‐risk clinical or genetic factors represented outcome extremes (median OS=18.3 vs. 74.2 months, p<0.001), with high‐risk genetic alterations alone (median OS=38.6 months, 95%CI=28.8‐73.5) or high‐risk clinical variables alone (median OS=37.0 months, 95%CI=27.6‐NA) associated with intermediate outcome. <i>TP53mut, KRASmut,</i> and <i>CDKN2Adel</i> similarly predicted worse outcome in patients with unresectable iCCA. <i>CDKN2Adel</i> tumors with high‐risk clinical features were notable for limited survival and no benefit of resection over chemotherapy. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p><i>TP53</i>, <i>KRAS,</i> and <i>CDKN2A</i> alterations were independent prognostic factors in iCCA when controlling for clinical and pathologic variables, disease stage, and treatment. Since genetic profiling can be integrated into pre‐treatment therapeutic decision‐making, combining clinical variables with targeted tumor sequencing may identify patient subgroups with poor outcome irrespective of treatment strategy. </p></section>

Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma

Mutational landscape of intrahepatic cholangiocarcinoma

Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.

Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets

Whole-Genome DNA Methylation Profiling of Intrahepatic Cholangiocarcinoma Reveals Prognostic Subtypes with Distinct Biological Drivers

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues

Revealing Clonality and Subclonality of Driver Genes for Clinical Survival Benefits in Breast Cancer.

The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations

Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.

Distinct Clinical and Prognostic Implication of IDH1/2 Mutation and Other Most Frequent Mutations in Large Duct and Small Duct Subtypes of Intrahepatic Cholangiocarcinoma

Implications of Driver Genes Associated with a High Tumor Mutation Burden Identified Using Next-Generation Sequencing on Immunotherapy in Hepatocellular Carcinoma.

Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma

Prognostic Values Of Prevalent Gene Mutations In Intrahepatic Cholangiocarcinoma

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

Genetic Profiling of Intrahepatic Cholangiocarcinoma and Its Clinical Implication in Targeted Therapy.